Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails

  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

Universal screening for the sexually transmitted diseases (STDs) of chlamydia and gonorrhea on intake in jails has been proposed as the most effective strategy to decrease morbidity in inmates and to reduce transmission risk in communities after release. Most inmates come from a population that is at elevated risk for STDs and has limited access to health care. However, limited resources and competing priorities force decision makers to consider the cost of screening programs in comparison to other needs. The costs and cost-effectiveness of universal screening in correctional settings have not been documented. We estimated the incremental cost-effectiveness of universal urine-based screening for chlamydia and gonorrhea among inmates on intake in US jails compared to the commonly used practice of presumptive treatment of symptomatic inmates without laboratory testing. Decision analysis models were developed to estimate the cost-effectiveness of screening alternatives and were applied to hypothetical cohorts of male and female inmates. For women, universal screening for chlamydia only was cost-saving to the health care system, averting more health care costs than were incurred in screening and treatment. However, for men universal chlamydia screening cost $4,856 more per case treated than presumptive treatment. Universal screening for both chlamydia and gonorrhea infection cost the health care system $3,690 more per case of pelvic inflammatory disease averted for women and $650 more per case of infection treated for men compared to universal screening for chlamydia only. Jails with a high prevalence of chlamydia and gonorrhea represent an operationally feasible and cost-effective setting to universally test and treat women at high risk for STDs and with limited access to care elsewhere.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Commission on Correctional Health Care. The Health Status of Soon-to-Be-Released Inmates: a Report to Congress. Chicago, IL: National Commission on Correctional Health Care; 2002.

    Google Scholar 

  2. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789–1794.

    PubMed  Google Scholar 

  3. Mertz KJ, Schwebke JR, Gaydos CA, Beidinger HA, Tulloch SD, Levine WC. Screening women in jails for chlamydia and gonococcal infection using urine tests: Feasibility, acceptability, prevalence, and treatment rates. Sex Transm Dis. 2002;29:271–276.

    PubMed  Google Scholar 

  4. Puisis M, Levine WC, Mertz KJ. Overview of sexually transmitted diseases in correctional facilities. In: Puisis M, Anno BJ, Cohen RL, et al., eds. Clinical Practice in correctional Medicine. St. Louis, MO: Mosby; 1998:129–135.

    Google Scholar 

  5. Holmes MD, Safyer SM, Bickell NA, Vermund SH, Hanff PA, Phillips RS. Chlamydial cervical infection in jailed women. Am J Public Health. 1993;83:551–555.

    CAS  PubMed  Google Scholar 

  6. Bickell NA, Vermund SH, Holmes MD, Safyer SM, Burk RD. Human papillomavirus, gonorrhea, syphilis, and cervical dysplasia in jailed women. Am J Public Health. 1991;81:1318–1320.

    Article  CAS  PubMed  Google Scholar 

  7. Division of STD Prevention. Sexually Transmitted Disease Surveillance, 2000. Atlanta, GA: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 2001.

    Google Scholar 

  8. Glaser JB, Greifinger RB. Correctional health care: a public health opportunity. Ann Intern Med. 1993;118:139–145.

    CAS  PubMed  Google Scholar 

  9. Glaser JB. Sexually transmitted diseases in the incarcerated. An underexploited public health opportunity [editorial]. Sex Transm Dis. 1998;25:308–309.

    CAS  PubMed  Google Scholar 

  10. Conklin TJ, Lincoln T, Tuthill RW. Self-reported health and prior health behaviors of newly admitted correctional inmates. Am J Public Health. 2000;90:1939–1941.

    CAS  PubMed  Google Scholar 

  11. Centers for Disease Control and Prevention. STD Services in Jails: an Opportunity to Improve the Health of the Larger Community. Results From the 1997 STD Correctional Health Assessment. Atlanta, GA: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 1998.

    Google Scholar 

  12. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61–77.

    CAS  PubMed  Google Scholar 

  13. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17.

    CAS  PubMed  Google Scholar 

  14. Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr. 2000;24:48–56.

    CAS  PubMed  Google Scholar 

  15. National Commission on Correctional Health Care. Standards for Health Services in Jails. Chicago, IL: National Commission on Correctional Health Care; 1996.

    Google Scholar 

  16. Stamm WE. Toward control of sexually transmitted chlamydial infections. Ann Intern Med. 1993;119:432–434.

    CAS  PubMed  Google Scholar 

  17. Institute of Medicine. The neglected health and economic impact of STD. In: Eng TR, Butler WT, eds. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press; 1997:28–68.

    Google Scholar 

  18. Marrazzo JM, White CL, Krekeler B, et al. Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay. Ann Intern Med. 1997;127:796–803.

    CAS  PubMed  Google Scholar 

  19. Oh MK, Smith KR, O'Cain M, Kilmer D, Johnson J, Hook EW. Urine-based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections. Arch Pediatr Adolesc Med. 1998;152:52–56.

    CAS  PubMed  Google Scholar 

  20. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. 2003;36:502–509.

    Article  PubMed  Google Scholar 

  21. Kamb ML, Newman D, Peterman TA, et al. Most bacterial STD are asymptomatic [abstract]. Presented at: STIs at the Millennium Conference; May 3–7, 2000; Baltimore, MD.

  22. Mertz KJ, Voigt RA, Hutchins K, Levine WC, the Jail STD Prevalence Monitoring Group. Findings from STD screening of adolescents and adults entering corrections facilities: implications for STD control strategies. Sex Transm Dis. 2002;29:834–839.

    PubMed  Google Scholar 

  23. Parece MS, Herrera GA, Voigt RF, Middlekauff SL, Irwin KL. STD testing policies and practices in US city and county jails. Sex Transm Dis. 1999;26:431–437.

    CAS  PubMed  Google Scholar 

  24. Cohen D, Scribner R, Clark J, Cory D. The potential role of custody facilities in controlling sexually transmitted diseases. Am J Public Health. 1992;82:552–556.

    CAS  PubMed  Google Scholar 

  25. Beltrami JF, Cohen DA, Hamrick JT, Farley TA. Rapid screening and treatment for sexually transmitted diseases in arrestees: a feasible control measure. Am J Public Health. 1997;87:1423–1426.

    CAS  PubMed  Google Scholar 

  26. Centers for Disease Control and Prevention. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections—2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR-15):1–40.

    Google Scholar 

  27. Berger RE. Acute epididymitis. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999:847–858.

    Google Scholar 

  28. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

    Google Scholar 

  29. Haddix AC, Teutsch SM, Corso PS, eds. Prevention Effectiveness: a Guide to Decision Analysis and Economic Evaluation. 2nd ed. New York: Oxford University Press; 2003.

    Google Scholar 

  30. Hammett TM. Making the case for health interventions in correctional facilities. J Urban Health. 2001;78:236–240.

    CAS  PubMed  Google Scholar 

  31. Dicker LW, Mosure DJ, Berman SM, Levine WC, Regional Infertility Prevention Program. Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000. Sex Transm Dis. 2003;30:472–476.

    PubMed  Google Scholar 

  32. Washington AE, Johnson RE, Sanders LL. Chlamydia trachomatis infections in the United States. What are they costing us? JAMA. 1987;257:2070–2072.

    Article  CAS  PubMed  Google Scholar 

  33. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis. 1995;22:274–280.

    CAS  PubMed  Google Scholar 

  34. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol. 2002;100:456–463.

    Article  PubMed  Google Scholar 

  35. Douglas JM, Newman D, Bolan G, et al. Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection [abstract]. Int J STD AIDS. 2001;12(suppl 2):65.

    Google Scholar 

  36. Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med. 1996;124:89–99.

    Google Scholar 

  37. Gift T, Owens C. The direct medical costs of epididymitis and orchitis: evidence from an analysis of insurance claims [abstract]. Presented at: ISSTDR Congress; July 28–30, 2003; Ottawa, Ontario, Canada.

  38. Rein D, Kassler W, Irwin K, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol. 2000;95:397–402.

    Article  CAS  PubMed  Google Scholar 

  39. Shafer MA, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med. 1999;153:119–125.

    CAS  PubMed  Google Scholar 

  40. Hook EW, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999; 451–466.

    Google Scholar 

  41. Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999: 407–422.

    Google Scholar 

  42. Risser JMH, Risser WL, Gefter LR, Brandstetter DM, Cromwell PF. Implementation of a screening program for chlamydial infection in incarcerated adolescents. Sex Transm Dis. 2001;28:43–44.

    CAS  PubMed  Google Scholar 

  43. Oh MK, Cloud GA, Wallace LS, Reynolds J, Sturdevant M, Feinstein RA. Sexual behavior and sexually transmitted diseases among male adolescents in detention. Sex Transm Dis. 1994;21:127–132.

    CAS  PubMed  Google Scholar 

  44. Van Der Pol B, Ferrero DV, Buck-Barrington L, et al. Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol. 2001;39:1008–1016.

    Article  Google Scholar 

  45. Howell MR, Quinn TC, Brathwaite W, Gaydos CA. Screening women for Chlamydia trachomatis in family planning clinics. The cost-effectiveness of DNA amplification assays. Sex Transm Dis. 1998;25:108–115.

    CAS  PubMed  Google Scholar 

  46. Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol. 1998;36:94–99.

    CAS  PubMed  Google Scholar 

  47. Association of Public Health Laboratories. 2001 Sexually Transmitted Diseases Laboratory Test Method Survey [report]. Washington, DC: Association of Public Health Laboratories; 2002:1–19.

    Google Scholar 

  48. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR-6):32–42.

    Google Scholar 

  49. Medical Economics Company. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001.

    Google Scholar 

  50. Gift T, Varghese B, Kraut, J, et al. The cost-effectiveness of jail-based STD and HIV prevention programs and their impact on inmate and community health [abstract]. Presented at: National STD Prevention Conference; March 4–7, 2002; San Diego, CA.

  51. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for treatment of chlamydial urethritis and cervicitis. N Engl J Med. 1992;327:921–925.

    Article  CAS  PubMed  Google Scholar 

  52. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54–62.

    CAS  PubMed  Google Scholar 

  53. Bureau of Justice Statistics. Women Offenders. Washington, DC: Bureau of Justice Statistics; December 1999. Special Report NCJ-175688.

    Google Scholar 

  54. Marrazzo JM, Celum CL, Hillis SD, Fine D, DeLisle S, Handsfield HH. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women, implications for a national chlamydia control strategy. Sex Transm Dis. 1997;24:131–141.

    Article  CAS  PubMed  Google Scholar 

  55. Brocklehurst P. Update on the treatment of sexually transmitted infections in pregnancy-1. Int J STD AIDS. 1999;10:571–580.

    Article  CAS  PubMed  Google Scholar 

  56. Hammerschlag MR. Chlamydial infections in infants and children. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999:1155–1164.

    Google Scholar 

  57. Ostergaard L. Diagnosis of urogenital Chlamydia trachomatis infection by use of DNA amplification. APMIS. 1999;107(suppl 89):5–36.

    Google Scholar 

  58. Gutman LT. Gonococcal diseases in infants and children. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999:1145–1153.

    Google Scholar 

  59. Bureau of Labor Statistics. Consumer price index—all urban consumers; 2003. [Database on the Internet]. Available at: http://www.bls.gov/cpihome.htm. Accessed June 16, 2003.

  60. Lenderman CJ, Jones M, Hook III EW. Comparison of the Binax Now gonorrhea test with Abbott LCR and culture for the detection of Neisseria gonorrhoeae in men and women [abstract]. Int J STD AIDS. 2002;12(suppl 1):98.

    Google Scholar 

  61. Young H, Moyes A, Tideman R, McMillan A. The Binax NOW test for the rapid diagnosis of gonorrhoeae in men [abstract]. Int J STD AIDS. 2002;12(suppl 1):98.

    Google Scholar 

  62. Theodore M, Hook EW III, Mableton S, Whittington WLH, Gaydos CA. Use of Thermo BioStar optical immunoassay (OIA) as a point of care assay for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in sexually transmitted disease clinics [abstract]. Int J STD AIDS. 2002;12(suppl 1):118.

    Google Scholar 

  63. Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health. 1999;88:1249–1250.

    Google Scholar 

  64. Skolnick AA. Correctional and community health care collaborations. JAMA. 1998; 279:98–99.

    Article  CAS  PubMed  Google Scholar 

  65. Richie BE, Freudenberg N, Page J. Reintegrating women leaving jail into urban communities: a description of a model program. J Urban Health. 2001;78:290–303.

    CAS  PubMed  Google Scholar 

  66. Gift TL, Walsh C, Haddix AC, Irwin KL. A cost effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis. 2002;29:542–551.

    PubMed  Google Scholar 

  67. Kacena KA, Quinn SB, Howell, MR, et al. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol. 1998;36:481–485.

    CAS  PubMed  Google Scholar 

  68. Kacena KA, Quinn SB, Hartman SC, Quinn TC, Gaydos CA. Pooling of urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol. 1998;36:3624–3628.

    CAS  PubMed  Google Scholar 

  69. Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Transm Infect. 1998;74:66–70.

    CAS  PubMed  Google Scholar 

  70. Krepel J, Patel J, Sproston A, et al. The impact on accuracy and cost of ligase chain reaction testing by pooling urine specimens for the diagnosis of Chlamydia trachomatis infections. Sex Transm Dis. 1999;26:504–507.

    CAS  PubMed  Google Scholar 

  71. Morre SA, Meijer CJLM, Munk C, et al. Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. J Clin Microbiol. 2000;38:1679–1680.

    CAS  PubMed  Google Scholar 

  72. Centers for Disease Control and Prevention. Notice to readers: discontinuation of cefixime tablets—United States. MMWR Morb Mortal Wkly Rep. 2002;51:1052.

    Google Scholar 

  73. Centers for Disease Control and Prevention. Increases in flouroquinolone-resistant Neisseria gonorrhoeae—Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1041–1044.

    Google Scholar 

  74. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20(suppl 1):S47-S65.

    PubMed  Google Scholar 

  75. Bala M, Ray K, Kumari S. Alarming increase in ciprofloxacin- and penicillin-resistant Neisseria gonorrhoeae isolates in New Delhi, India. Sex Transm Dis. 2003;30:523–525.

    CAS  PubMed  Google Scholar 

  76. Augenbraun M, Bachmann L, Wallace T, Dubouchet L, McCormack W, Hook EW. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis. 1998;25:1–4.

    CAS  PubMed  Google Scholar 

  77. Handsfield HH, Stamm WE. Treating chlamydial infection: compliance versus cost [editorial]. Sex Transm Dis. 1998;25:12–13.

    CAS  PubMed  Google Scholar 

  78. Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics: a cost-effectiveness analysis of three strategies. Ann Intern Med. 1998;128:277–284.

    CAS  PubMed  Google Scholar 

  79. Mehta SD, Bishai D, Howell MR, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis. 2002;29:83–91.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Studies of Addiction, University of Pennsylvania, 3535 Market Street, Fourth Floor, Suite 4000, 19104-3309, Philadelphia, PA

    Julie R. Kraut-Becher PhD

  2. Department of Economics, Swarthmore College, Swarthmore, Pennsylvania

    Julie R. Kraut-Becher PhD

  3. Division of Sexually Transmitted Diseases Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

    Thomas L. Gift &  Kathleen L. Irwin

  4. Rollins School of Public Health, Emory University, Atlanta, Georgia

    Anne C. Haddix &  Robert B. Greifinger (Correctional Healthcare Consultant)

Authors
  1. Julie R. Kraut-Becher PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas L. Gift
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne C. Haddix
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathleen L. Irwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert B. Greifinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie R. Kraut-Becher PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kraut-Becher, J.R., Gift, T.L., Haddix, A.C. et al. Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails. J Urban Health 81, 453–471 (2004). https://doi.org/10.1093/jurban/jth130

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/jth130

Keywords

Search

Navigation